![]() |
市場調查報告書
商品編碼
1439338
青光眼引流裝置 - 全球市場回顧、競爭格局、市場預測(2030)Glaucoma Drainage Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
預計,2023年全球青光眼引流裝置市場規模將達6.4057億美元,到2030年將達到11.8439億美元,預計2024-2030年期間複合年增長率為11.95%。 青光眼引流裝置需求的增加主要是由於全球範圍內青光眼盛行率的上升、糖尿病、高血壓等生活習慣疾病的增加、人口老齡化負擔的加重以及產品開發方面的技術創新,這些是預計將推動青光眼引流裝置市場的發展。
青光眼引流裝置市場動態
青光眼引流裝置需求增加的主要因素是全球青光眼盛行率的上升。 例如,根據德裡眼科協會2022年提供的數據,青光眼是全球不可逆失明的主要原因。 據同一消息來源稱,2020年,全球青光眼負擔估計為7,960萬人。 另外,根據前述資料,印度預計將成為青光眼患者數量第二多的地區,預計2020年印度青光眼患者盛行率為1190萬人。 因此,青光眼盛行率的增加可能會在預測期內(2024-2030年)推動青光眼設備市場的發展。
此外,導致青光眼引流裝置市場成長的另一個主要因素可能是糖尿病和高血壓盛行率的增加。 例如,根據世界衛生組織(WHO)2023年發布的數據,2020年全球約有4.22億人患有糖尿病,每年約有150萬人患有糖尿病。 因此,糖尿病使青光眼的機會增加一倍,如果不及早治療,可能會導致視力喪失和失明,從而在預測期內(2024-2030)推動青光眼設備市場的需求。
此外,根據泛美衛生組織2020年發布的最新數據,全球超過30%的成年人口患有高血壓,影響全球超過10億人。 此外,根據世界衛生組織2023年發布的數據,2020年中國約有2.7億人患有高血壓。 此外,高血壓會損害眼睛的動脈,使其無法適應因眼內壓升高而導致的血流變化,並被認為是青光眼的危險因子。
展望未來,上述因素將有助於預測期內全球青光眼引流裝置市場的成長。
然而,與設備相關的併發症和青光眼引流設備有限的功效預計將對青光眼引流設備市場的成長構成挑戰。
此外,在COVID-19大流行期間,全球青光眼手術數量和公司收入部分大幅下降,短期限制了青光眼引流裝置市場的成長。 不過,隨著2020年下半年Glaukos公司新一代青光眼引流器iStent Inject W等多款產品的上市,全球青光眼引流機市場可望在疫情後的情況下復甦。 此外,隨著封鎖規定的放鬆和擇期手術的恢復,以及更明確的預防方法和指南,青光眼引流裝置市場可能會再次成長。 此外,2020 年下半年,全球多種 COVID-19 疫苗的批准和管理導致包括醫療保健服務在內的各個領域的活動強勁復甦,為青光眼引流裝置的健康恢復階段鋪平了道路市場。道路已經開通。
青光眼引流管市場區隔分析
按青光眼引流裝置市場的產品細分來看,微創青光眼手術裝置 (MIGS) 類別預計將佔據市場主導地位,到 2030 年和 2024-2030 年預測期間將達到 6.8146 億美元。預計增長複合年增率為11.95%。
本報告研究和分析了全球青光眼引流裝置市場,提供市場規模和預測、驅動因素和挑戰、公司和產品概況等。
Glaucoma Drainage Devices Market By Product Type (Conventional Glaucoma Drainage Devices [Valveless Glaucoma Drainage Devices And Valved Glaucoma Drainage Devices], Minimally Invasive Glaucoma Surgery (Migs) Devices [Schlemm's Canal Migs Devices, Suprachoroidal Migs Devices, And Subconjunctival Migs Devices]), By End-User (Hospitals, Ambulatory Surgical Centers, And Specialty Clinics), by geography, is anticipated to grow at a significant CAGR forecast till 2030 due to rising prevalence of glaucoma and increasing prevalence of diabetes & hypertension
The global glaucoma drainage devices market was valued at USD 640.57 million in 2023, growing at a CAGR of 11.95% during the forecast period from 2024 to 2030, to reach USD 1,184.39 million by 2030. The increase in demand for glaucoma drainage devices is primarily due to the rising prevalence of glaucoma across the globe, increasing lifestyle disorders such as diabetes & hypertension, the growing burden of the old age population, and technical innovation in product development are expected to boost the market for glaucoma drainage devices.
Glaucoma Drainage Devices Market Dynamics:
The key factor responsible for the increasing demand for glaucoma drainage devices is the rising prevalence of glaucoma conditions worldwide. For instance, as per the data provided by the Delhi Ophthalmological Society in 2022, glaucoma is the leading cause of irreversible blindness across the world. As per the same source, in 2020, the global burden of glaucoma was estimated to be 79.6 million. Also, according to the aforementioned source, India is expected to be the second-largest home of glaucoma patients, and the estimated prevalence of glaucoma cases in India was estimated to be 11.9 million in 2020. Therefore, the increasing prevalence of glaucoma could boost the glaucoma devices market during the forecast period (2024-2030).
Further, another key factor that is responsible for the growth of the glaucoma drainage devices market could be the increasing prevalence of diabetes & hypertension. For instance, as per the World Health Organization data published in the year 2023, in 2020, about 422 million people worldwide had diabetes, and about 1.5 million people suffer from diabetes every year. Thus, diabetes doubles the chances of having glaucoma, which can lead to vision loss and blindness if not treated early, which can increase the glaucoma devices market demand during the forecast period (2024-2030).
Furthermore, according to the latest data published by Pan American Health Organization in 2020, hypertension had affected more than 30% of the adult population worldwide, accounting for more than one billion people around the world. Also, as per the data published by World Health Organization in the year 2023, in 2020, about 270 million people were affected by hypertension in China. Moreover, the blood arteries in the eyes may be damaged by hypertension and unable to adjust to changes in blood flow as a result of rising ocular pressure, which is considered to be a risk factor for glaucoma.
Henceforth, the above-mentioned factors will contribute to the global glaucoma drainage devices market growth during the forecasted period.
However, complications associated with the devices and efficacy of glaucoma drainage devices for a limited timeframe are expected to pose a challenge to the glaucoma drainage devices market growth.
Additionally, there was a significant reduction in the glaucoma surgical volume procedures and company revenue segments across the globe during the COVID-19 pandemic, which restricted the glaucoma-drainage device market growth for a brief period. However, due to the launch of several products such as the iStent inject W by Glaukos Corporation, a next-generation glaucoma drainage device, in the second half of 2020, the glaucoma drainage devices market potentially redeem itself across the globe in the post-pandemic scenario. Also, the easing of lockdown restrictions and resumed elective surgeries along with more clear precautionary approaches and guidelines lead to the renewed market growth of glaucoma drainage devices. Moreover, owing to the approval and administration of numerous COVID-19 vaccines across the globe in the second half of 2020, there was a significant improvement in the resumption of activities across various domains, including healthcare services, thereby paving the way for a sound period of recovery for the glaucoma drainage devices market.
Glaucoma Drainage Devices Market Segment Analysis:
Glaucoma Drainage Devices Market By Product Type (Conventional Glaucoma Drainage Devices [Valveless Glaucoma Drainage Devices and Valved Glaucoma Drainage Devices], Minimally Invasive Glaucoma Surgery (MIGS) Devices [Schlemm's Canal MIGS Devices, Suprachoroidal MIGS Devices, and Subconjunctival MIGS Devices]), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product segment of the glaucoma drainage devices market, the Minimally Invasive Glaucoma Surgery devices (MIGS) category is expected to dominate the market and is estimated to grow at a CAGR of 11.95% during the forecast period from 2024-2030 to reach USD 681.46 million by 2030. The MIGS devices are categorized into Schlemm's Canal MIGS Devices, Suprachoroidal MIGS Devices, and Subconjunctival MIGS Devices. Schlemm's canal MIGS devices are used to increase trabecular outflow by bypassing the trabecular meshwork and directing aqueous humor into Schlemm's canal. Since the trabecular meshwork is considered the primary site of resistance to aqueous humor outflow, bypassing this structure and directing aqueous flow from the anterior chamber directly into Schlemm's canal seemed to be a reasonable approach that increases the demand for these devices.
Moreover, as per the various studies, the Intraocular Pressure (IOP)-lowering efficacy of subconjunctival MIGS appears to approach that of traditional filtering surgery, thereby offering the possibility that they might have utility in more advanced or normal-pressure glaucoma. Further, recently, in May 2022, PRESSERFLO, subconjunctival MIGS devices, was approved by Health Canada to reduce in patients with primary open-angle glaucoma (POAG) whose IOP is not controlled when using maximum tolerated glaucoma medications
Hence, all the aforementioned factors will lead to the segmental growth of the glaucoma drainage devices market in the coming years.
North America is expected to dominate the overall Glaucoma Drainage Devices Market:
Among all the regions, North America dominated the market in the year 2023 and is estimated to grow at a CAGR of 11.06% during the forecast period from 2024 to 2030 to reach USD 453.39 million by 2030. This domination can be primarily attributed to the rising cases of lifestyle-related disorders such as diabetes and the rising geriatric population.
For instance, as per the National Diabetics Statistics Report published by the Centers for Disease Control and Prevention (CDC) in the year 2020, about 34.2 million Americans had diabetes 2020. The report further stated that approximately 88 million Americans showed pre-diabetes levels. The CDC considers diabetes to be one of the major risk factors that may lead to glaucoma development. Thus, diabetes doubles the chances of having glaucoma, which can lead to vision loss and blindness if not treated early, which can increase the glaucoma devices market demand during the forecast period (2024-2030).
According to the data published by the World Bank Group in the year 2023, approximately 9,822,231 population in Mexico were aged 65 years and above in 2020. Thus, the geriatric population is more susceptible to developing glaucoma is also expected to raise the demand for glaucoma drainage devices in the upcoming years.
The market presence of key manufacturers such as Johnson & Johnson, Allergan, and others active in manufacturing glaucoma drainage devices will also contribute to the market growth of these devices.
Thus, all the above-mentioned factors are projected to surge the market for glaucoma drainage devices in the region.
Glaucoma Drainage Devices Market Key Players:
Some of the key market players operating in the glaucoma drainage devices market include Johnson & Johnson, AbbVie Inc, Alcon Inc, Glaukos Corporation, Santen Pharmaceutical Co., Ltd, NovaEye Medical Limited, iSTAR Medical SA, Rheon Medical SA, Advanced Ophthalmic Innovations Pte Ltd, New World Medical Inc, Aurolab, and others.
Recent Developmental Activities in the Glaucoma Drainage Devices Market:
In October 2022, Alcon, the world leader in eye care committed to enabling people to see brilliantly, announced the completion of its previously announced acquisition of Ivantis®, maker of the ground-breaking Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) tool intended to reduce eye pressure for open-angle glaucoma patients in conjunction with cataract surgery.
In November 2022, iSTAR Medical a MedTech company committed to delivering breakthrough eye care solutions through minimally-invasive implants designed for bio-integration, received European market approval for glaucoma implant MINIject designed to significantly reduce IOP by enhancing aqueous humor outflow from the anterior chamber to the suprachoroidal space.
In May 2022, Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., a global company focused on developing ophthalmology products, received Health Canada approval for PRESERFLOTM MicroShunt. This surgical device helps drain eye fluid and reduce intraocular pressure (IOP) in patients with POAG.
Key Takeaways from the Glaucoma Drainage Devices Market Report Study:
Target Audience who can be benefited from the Glaucoma Drainage Devices Market Report Study
Frequently Asked Questions for the Glaucoma Drainage Devices Market:
Glaucoma drainage devices have been designed to divert the aqueous humor from the anterior chamber to the external reservoir. A fibrous capsule is formed in about 4-6 weeks after the surgery and regulates the flow. The devices are extensively used in complicated glaucoma, comprising uveitic glaucoma, neovascular glaucoma, and pediatric and developmental glaucoma.
The global glaucoma drainage devices market was valued at USD 640.57 million in 2023, growing at a CAGR of 11.95% during the forecast period from 2024 to 2030, to reach USD 1,184.39 million by 2030.
The major factors driving the demand for glaucoma drainage devices are the rising prevalence of glaucoma across the globe, increasing lifestyle disorders such as diabetes & hypertension, the growing burden of the old age population, and technical innovation in product development.
Some of the key market players operating in the glaucoma drainage devices market include Johnson & Johnson, AbbVie Inc, Alcon Inc, Glaukos Corporation, Santen Pharmaceutical Co., Ltd, NovaEye Medical Limited, iSTAR Medical SA, Rheon Medical SA, Advanced Ophthalmic Innovations Pte Ltd, New World Medical Inc, Aurolab, and others.
Among all the regions, North America is expected to occupy a major share in the overall glaucoma drainage devices market during the forecasted years, 2024-2030. This domination can be primarily attributed to the rising cases of lifestyle-related disorders such as diabetes and the rising geriatric population.